Company
exonate.com
We are a biotechnology company with a mission to profoundly improve treatment options for diabetic retinopathy patients through the creation of powerful targeted eyedrops.
Also known as Foventa Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Our lead asset, FOV407 will enter Phase IIb clinical trials in 2026 and is poised to become the first topical therapy for non-proliferative diabetic retinopathy (NPDR).
Products
- Other
- FOV407
Loading relationship preview